Text Size

Early Diabetes Resolution After Weight Loss Surgery

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Naji Abumrad, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00790309
First received: November 11, 2008
Last updated: June 8, 2012
Last verified: June 2012
History of Changes

November 11, 2008
June 8, 2012
December 2008
November 2012   (final data collection date for primary outcome measure)
 
 
Complete list of historical versions of study NCT00790309 on ClinicalTrials.gov Archive Site
 
 
 
 
 
Early Diabetes Resolution After Weight Loss Surgery
Hormonal and Inflammatory Parameters Affecting Early Diabetes Resolution Following Weight Loss Surgery

The primary objective is to compare inflammatory, hormonal, and metabolic changes in the very short term after various bariatric surgical procedures (Roux-en Y Gastric Bypass, Vertical Sleeve Gastrectomy, and Adjustable Gastric Banding)and other abdominal surgeries, as well as to compare these changes to diet-induced changes in the same population.
 
Observational
Observational Model: Case Control
Time Perspective: Prospective
Retention:   Samples With DNA
Description:

plasma and serum
Non-Probability Sample

Subjects scheduled for weight loss surgery or other abdominal surgeries will be considered for the study.
  • Obesity
  • Diabetes
  • Procedure: Weight loss surgery
    Weight loss surgery
  • Procedure: Laparoscopic abdominal surgeries
    laparoscopic abdominal surgeries
  • Weight loss surgery
    This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
    Intervention: Procedure: Weight loss surgery
  • Abdominal surgery
    This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
    Intervention: Procedure: Laparoscopic abdominal surgeries
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
60
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI of 35kg/m2 or higher
  • Ages 18-65
  • History of impaired glucose tolerance or T2DM

Exclusion Criteria:

  • Development of an intercurrent infection
  • Prior gastric, duodenal, proximal jejunal surgery or pancreas resection
  • Current use of thiazolidinediones
  • Current use of dipeptidyl peptidase-IV inhibitors (e.g., sitagliptin) or glucagon-like peptide-1 analogs (e.g., exanatide)
  • Any condition felt by the PI or co-investigators to interfere with ability to complete the study
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00790309
NNA-Early DM Resolution
No
Naji Abumrad, Vanderbilt University
Vanderbilt University
 
Principal Investigator: Naji Abumrad, MD Vanderbilt University
Vanderbilt University
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP